Welcome to our dedicated page for Bio Rad Labs news (Ticker: BIO), a resource for investors and traders seeking the latest updates and insights on Bio Rad Labs stock.
Bio-Rad Laboratories, Inc. (NYSE: BIO, BIO.B) is described in its own communications as a leader in life science research and clinical diagnostics products. Based in Hercules, California, the company operates globally and regularly issues news on its financial performance, technology platforms, and corporate developments. This news page aggregates recent BIO stock headlines and company announcements.
Investors and analysts following Bio-Rad can find updates on quarterly financial results, including segment performance for the Life Science and Clinical Diagnostics groups and commentary on factors such as academic research funding, biotech funding conditions, and reimbursement trends in key markets. The company frequently discusses both GAAP and non-GAAP results, along with explanations of how non-GAAP measures are used in its internal analysis.
Bio-Rad’s news flow also covers product and technology updates, particularly around its Droplet Digital PCR (ddPCR) portfolio. Recent releases describe the launch of new ddPCR platforms, the integration of technologies from the acquisition of Stilla Technologies, and webinars or presentations focused on its ddPCR product line. These items provide insight into how the company is expanding its presence in genomics research and applied science applications.
Additional news items include announcements about participation in healthcare and investor conferences, leadership appointments, and historical and corporate milestones. For example, the company has reported on executive leadership changes and has issued statements regarding the passing of its co-founder and Director Emeritus, Alice N. Schwartz. Users interested in BIO news can use this page to review these updates in one place and to track how Bio-Rad communicates its strategy and operations over time.
Bio-Rad (NYSE: BIO) will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026 after market close. Management will host a conference call at 2:00 PM PT / 5:00 PM ET to discuss results.
To join, dial domestic or international numbers with access code 9562470, or use the live webcast and supplemental presentation in the Investor Relations "Events & Presentations" section. A replay will be available for up to one year.
Bio-Rad (NYSE: BIO / BIO.B) said its CEO Norman Schwartz, COO Jon DiVincenzo, and CFO Roop K. Lakkaraju will hold one-on-one meetings with analysts and investors at J.P. Morgan's 44th Annual Healthcare Conference in San Francisco, CA, January 12–15, 2026.
The meetings are scheduled as part of the company's participation in the conference and are intended to provide investor engagement and updates on corporate strategy and operations.
Bio-Rad (NYSE: BIO) reported Q3 2025 results for the quarter ended September 30, 2025: total net sales $653.0M (+0.5% vs Q3 2024; currency-neutral -1.7%).
GAAP results included a $341.9M net loss (or $(12.70) per diluted share) driven substantially by a change in fair value of its Sartorius investment; Q3 2024 GAAP net income was $653.2M.
On a non-GAAP basis, Q3 net income was $60.8M ($2.26 per share) vs $56.3M ($2.02) in Q3 2024. Company reaffirmed full-year 2025 non-GAAP guidance: currency-neutral revenue growth ~0–1% and non-GAAP operating margin ~12–13%.
Bio-Rad (NYSE: BIO) will report Q3 2025 financial results on Wednesday, October 29, 2025 after market close. Management will host a conference call the same day at 2:00 PM PT / 5:00 PM ET.
Dial-in numbers: (800) 715-9871 (U.S.) or (646) 307-1963 (international); access code 9562470. A live webcast and supplemental earnings presentation will be posted in the Investor Relations > Events & Presentations section at investors.bio-rad.com. A replay of the webcast will be available for up to one year.
Bio-Rad Laboratories (NYSE: BIO) announced the passing of co-founder and Director Emeritus Alice N. Schwartz on September 25, 2025, at age 99. Schwartz co-founded Bio-Rad in 1952 in Berkeley, California, alongside her husband David Schwartz after graduating with a biochemistry degree from UC Berkeley.
A pioneering figure in life science research, Schwartz was instrumental in developing Bio-Rad's first thyroid function test kit in the 1960s, marking the company's entry into clinical diagnostics. Her contributions helped transform Bio-Rad into a global leader in life science research and clinical diagnostics products. She remained an active Board member until 2022.
Bio-Rad Laboratories (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, has announced its executive leadership team's participation in two upcoming investor conferences.
At the 2025 Wells Fargo Healthcare Conference on September 4, Chairman and CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat and one-on-one meetings. The fireside chat will be webcast live at 12:45 PM ET. Additionally, CFO Roop K. Lakkaraju will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 for one-on-one investor meetings.
Bio-Rad Laboratories (NYSE: BIO and BIO.B) has announced an upcoming informational webinar focusing on their Droplet Digital PCR (ddPCR) product portfolio. The event is scheduled for August 26, 2025, at 10:00 AM Pacific Time.
The webinar will feature a presentation and Q&A session led by President and COO Jon DiVincenzo and CFO Roop K. Lakkaraju. Participants can join via phone or watch the live webcast through Bio-Rad's investor relations website, where the presentation will remain available for replay for up to one year.
Bio-Rad Laboratories (NYSE: BIO) reported Q2 2025 financial results with total net sales of $651.6 million, representing a 2.1% increase from Q2 2024. The Life Science segment grew 4.9% to $262.8 million, while Clinical Diagnostics remained flat at $388.8 million.
The company reported GAAP net income of $317.8 million ($11.67 per share), compared to a loss of $(2,165.5) million in Q2 2024, largely due to changes in Sartorius AG investment value. Non-GAAP net income was $71.0 million ($2.61 per share).
Bio-Rad updated its 2025 outlook, projecting non-GAAP currency-neutral revenue growth of 0 to 1.0% and improved operating margin guidance to 12.0-13.0%. The company also completed the acquisition of Stilla Technologies, expanding its Droplet Digital PCR portfolio.
Bio-Rad Laboratories (NYSE: BIO) has appointed Rajat Mehta as its new Executive Vice President of Global Commercial Operations, effective August 4, 2025. Mehta, who joins from Labcorp where he served as Senior Vice President, succeeds Mike Crowley, who is retiring after 26 years with Bio-Rad.
Mehta brings significant experience from leadership roles at Labcorp, Thermo Fisher Scientific, and Dow Chemical. He holds an MBA from The Wharton School and a BS in Electrical Engineering from Kurkshetra University. The appointment aims to advance Bio-Rad's long-term strategy in life science research and clinical diagnostics markets.
Bio-Rad Laboratories (NYSE: BIO, BIO.B), a leader in life science research and clinical diagnostics, has scheduled its Q2 2025 earnings release for July 31, 2025, after market close. The company will host a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss the results.
Investors can join via phone using the toll-free number (800) 715-9871 within the U.S. or (646) 307-1963 internationally, with access code 9562470. A live webcast and supplemental earnings presentation will be available on Bio-Rad's investor relations website, with the webcast replay accessible for up to one year.
FAQ
What is the current stock price of Bio Rad Labs (BIO)?
What is the market cap of Bio Rad Labs (BIO)?
